| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Experimental Pathology,* Cancer Research Section, University of Bologna, Bologna; the Istituti Ortopedici Rizzoli, Bologna; the Interdepartment Center for Cancer Research "G. Prodi," Bologna; the Istituto Nazionale per la Ricerca sul Cancro, IST, Genoa; the Department of Oncology and Neurosciences,¶ "G. D’Annunzio" University, Chieti; and the Department of Clinical and Biological Sciences,|| University of Turin, Orbassano, Italy
We previously showed that a vaccine combining interleukin 12 and allogeneic p185neu-positive mammary carcinoma cells completely prevented multifocal mammary carcinogenesis in HER-2/neu transgenic mice. To identify the molecular events responsible for effective tumor prevention and to define the tumor gene expression signature, we used microarrays to analyze the expression profile of mammary tissue of untreated transgenic mice and of vaccine-treated, tumor-free mice at different time points. Mammary tissue from vaccinated mice displayed a gene expression profile different from that of untreated, tumor-bearing mice but similar to that of normal/hyperplastic mammary gland. Comparison of treated and untreated mice at 15 weeks of age revealed up-regulation of genes encoding antibodies, chemokines, 
-interferon-induced genes and inflammatory molecules, and down-regulation of early genes induced by tumor development. The gene expression signature of HER-2/neu-transformed tumor cells showed modulation of genes promoting proliferation, angiogenesis, migration, invasion, and metastasis and inhibiting apoptosis and immune response. Meta-analysis of microarray data on human breast cancer showed that the signature of tumors arising in murine HER-2/neu transgenic model correctly classified human HER-2/neu-expressing tumors and normal breast tissue. Moreover murine and human HER-2/neu-positive tumors share the signature of basal-like breast cancers. This gene expression analysis reveals the immune events associated with prevention of tumor development and shows that HER-2/neu transgenic mice represent a good model of a poor-prognosis group of human breast tumors.
This article has been cited by other articles:
 |
|
 |
|
  M. P. Piechocki, G. H. Yoo, S. K. Dibbley, and F. Lonardo Breast Cancer Expressing the Activated HER2/neu Is Sensitive to Gefitinib In vitro and In vivo and Acquires Resistance through a Novel Point Mutation in the HER2/neu Cancer Res., July 15, 2007; 67(14): 6825 - 6843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Belguise, S. Guo, and G. E. Sonenshein Activation of FOXO3a by the Green Tea Polyphenol Epigallocatechin-3-Gallate Induces Estrogen Receptor {alpha} Expression Reversing Invasive Phenotype of Breast Cancer Cells Cancer Res., June 15, 2007; 67(12): 5763 - 5770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rolla, C. Nicolo, S. Malinarich, M. Orsini, G. Forni, F. Cavallo, and F. Ria Distinct and Non-Overlapping T Cell Receptor Repertoires Expanded by DNA Vaccination in Wild-Type and HER-2 Transgenic BALB/c Mice J. Immunol., December 1, 2006; 177(11): 7626 - 7633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Di Modugno, M. Mottolese, A. Di Benedetto, A. Conidi, F. Novelli, L. Perracchio, I. Venturo, C. Botti, E. Jager, A. Santoni, et al. The Cytoskeleton Regulatory Protein hMena (ENAH) Is Overexpressed in Human Benign Breast Lesions with High Risk of Transformation and Human Epidermal Growth Factor Receptor-2-Positive/Hormonal Receptor-Negative Tumors Clin. Cancer Res., March 1, 2006; 12(5): 1470 - 1478. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
